Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK6 | Q16659 | 6/20 | 0.36 |
| ▸ | ULK1 | O75385 | 2/20 | 0.36 |
| ▸ | ULK2 | Q8IYT8 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30838069 | 0.89 | IRAK4 (0.41) | IRAK4MAPK8MAPK6MCHR1ADORA2A | |
| SCHEMBL24288103 | 0.85 | IRAK4 (0.39) | IRAK4MAPK8MAPK6ADORA2AADORA1 | |
| SCHEMBL30838030 | 0.74 | ULK1 (0.39) | IRAK4ULK1MCHR1ADRA2AADRA1A | |
| SCHEMBL27095200 | 0.73 | MAPK8 (0.39) | IRAK4MAPK8MCHR1ADORA1ADRA2A | |
| SCHEMBL30838096 | 0.71 | CDK2 (0.40) | MAPK8ULK1MCHR1ADRA2AADRA1A | |
| SCHEMBL24288095 | 0.71 | MAPK8 (0.44) | MAPK8MAPK6MCHR1ADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL30838108 | 0.70 | MAPK8 (0.43) | MAPK8MAPK6MCHR1ADORA2AADORA1 | |
| SCHEMBL18830394 | 0.70 | MAPK6 (0.43) | IRAK4MAPK6MCHR1ADORA2AADRA2A | |
| SCHEMBL30837994 | 0.68 | MAPK8 (0.39) | IRAK4MAPK8MCHR1ADRA2AADRA1A | |
| Hydrochloric Acid SCHEMBL30838027 | 0.68 | MAPK8 (0.39) | IRAK4MAPK8MCHR1ADRA2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059677-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | CEREVANCE LTD (GB) | 2024-02-22 | — | — | US | claimed |
| US-20240059677-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | CEREVANCE LTD (GB) | 2024-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059677-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | CHRNA6, CHRM2, CHRNA1 | IRAK4 2416/4885MAPK8 4241/4885MAPK6 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.